X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immunomodulatory drug fty720 (83) 83
index medicus (72) 72
humans (59) 59
animals (58) 58
sphingosine - analogs & derivatives (55) 55
fingolimod hydrochloride (40) 40
multiple sclerosis (38) 38
experimental autoimmune encephalomyelitis (36) 36
sphingosine - pharmacology (32) 32
central-nervous-system (30) 30
fty720 (28) 28
propylene glycols - pharmacology (28) 28
pharmacology & pharmacy (27) 27
sphingosine 1-phosphate (27) 27
fingolimod (26) 26
mice (25) 25
sphingosine (25) 25
receptors, lysosphingolipid - metabolism (23) 23
immunosuppressive agents - pharmacology (22) 22
sphingosine-1-phosphate (22) 22
lymphocyte egress (20) 20
sphingosine - metabolism (20) 20
biochemistry & molecular biology (19) 19
lysophospholipids - metabolism (19) 19
multiple-sclerosis (19) 19
neurosciences (19) 19
phosphorylation (19) 19
multiple sclerosis - drug therapy (18) 18
phosphotransferases - metabolism (18) 18
sphingosine - therapeutic use (18) 18
sphingosine 1-phosphate receptors (18) 18
propylene glycols - therapeutic use (17) 17
immunosuppressive agents - therapeutic use (16) 16
sphingosine kinase (16) 16
oral fingolimod (15) 15
article (14) 14
sphingosine-1-phosphate receptors (14) 14
cell biology (13) 13
chemistry, medicinal (13) 13
lipids (13) 13
clinical neurology (12) 12
immunology (12) 12
protein-coupled receptor (12) 12
lymphocytes (11) 11
mice, inbred c57bl (11) 11
neurology (11) 11
protein-coupled receptors (11) 11
sphingosine 1-phosphate receptor (11) 11
administration, oral (10) 10
apoptosis (10) 10
encephalomyelitis, autoimmune, experimental - drug therapy (10) 10
phosphates (10) 10
phosphotransferases - genetics (10) 10
signal transduction - drug effects (10) 10
sphingosine - chemistry (10) 10
biomedicine (9) 9
male (9) 9
receptors, lysosphingolipid - agonists (9) 9
relapsing multiple-sclerosis (9) 9
research (9) 9
signal transduction (9) 9
cancer (8) 8
cells, cultured (8) 8
disease models, animal (8) 8
molecular-cloning (8) 8
placebo-controlled trial (8) 8
propylene glycols - chemistry (8) 8
review (8) 8
sphingolipids (8) 8
cells (7) 7
central nervous system - drug effects (7) 7
ceramide (7) 7
dose-response relationship, drug (7) 7
fingolimod hydrochloride - pharmacology (7) 7
health aspects (7) 7
hemic and lymphatic diseases (7) 7
immunosuppressant fty720 (7) 7
in-vivo (7) 7
inflammation (7) 7
lymphopenia (7) 7
mice, knockout (7) 7
molecular structure (7) 7
multiple sclerosis - immunology (7) 7
rats (7) 7
sphingosine - administration & dosage (7) 7
t-cells (7) 7
1-phosphate (6) 6
analysis (6) 6
central nervous system (6) 6
circulating mature lymphocytes (6) 6
drug therapy (6) 6
female (6) 6
functional-characterization (6) 6
immunomodulation (6) 6
kinases (6) 6
multiple sclerosis, relapsing-remitting - drug therapy (6) 6
allergy and immunology (5) 5
blood-brain-barrier (5) 5
cladribine (5) 5
development and progression (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neuroinflammation, ISSN 1742-2094, 05/2015, Volume 12, Issue 1, p. 86
Journal Article
Clinical Neuropharmacology, ISSN 0362-5664, 03/2010, Volume 33, Issue 2, pp. 91 - 101
Fingolimod (FTY720) is a first-in-class orally bioavailable compound that has shown efficacy in advanced clinical trials for the treatment of multiple... 
Sphingosine 1-phosphate receptor modulator | Multiple sclerosis | Fingolimod | Sphingosine 1-phosphate | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | T-CELL SUBSETS | multiple sclerosis | sphingosine 1-phosphate receptor modulator | PROTEIN-COUPLED RECEPTORS | CLINICAL NEUROLOGY | IMMUNOMODULATORY DRUG FTY720 | SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | fingolimod | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | INTRAMUSCULAR INTERFERON BETA-1A | sphingosine 1-phosphate | RAT CEREBROCORTICAL ASTROCYTES | 12-MONTH PHASE-III | Encephalomyelitis, Autoimmune, Experimental - metabolism | Sphingosine - adverse effects | Humans | Neuroglia - drug effects | Propylene Glycols - adverse effects | Sphingosine - administration & dosage | Neurons - drug effects | Receptors, Lysosphingolipid - metabolism | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Multiple Sclerosis - metabolism | Propylene Glycols - pharmacology | Administration, Oral | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Fingolimod Hydrochloride | Sphingosine - pharmacology | Models, Immunological | Sphingosine - analogs & derivatives | Animals | Propylene Glycols - administration & dosage | Immune System - drug effects | Lymphocytes - drug effects | Central Nervous System - drug effects | Receptors, Lysosphingolipid - agonists | Immunosuppressive Agents - adverse effects | Multiple Sclerosis - drug therapy
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2010, Volume 176, Issue 6, pp. 2682 - 2694
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 11/2009, Volume 158, Issue 5, pp. 1173 - 1182
FTY720 (fingolimod) is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was highly effective in Phase II clinical trials for Multiple... 
Multiple Sclerosis | infection | FTY720 (fingolimod) | S1P (sphingosine 1-phosphate) | autoimmunity | immunotherapy | central nervous system | S1P (sphingosine 1‐phosphate) | Autoimmunity | Infection | Multiple sclerosis | Immunotherapy | Central nervous system | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | T-CELL SUBSETS | S1P RECEPTORS | AGONISM IMPAIRS | IMMUNOMODULATORY DRUG FTY720 | SPHINGOSINE 1-PHOSPHATE RECEPTORS | MECHANISTIC INSIGHTS | ENDOTHELIAL-CELLS | PHARMACOLOGY & PHARMACY | HEART-RATE | SECONDARY LYMPHOID-TISSUES | T-Lymphocytes - physiology | Phosphorylation | Receptors, Lysosphingolipid - antagonists & inhibitors | Lymph Nodes - pathology | Humans | Astrocytes - pathology | Encephalomyelitis, Autoimmune, Experimental - immunology | Astrocytes - immunology | Propylene Glycols - therapeutic use | Receptors, Lysosphingolipid - genetics | Propylene Glycols - pharmacology | Sphingosine - physiology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Fingolimod Hydrochloride | Phosphotransferases (Alcohol Group Acceptor) - genetics | Receptors, Lysosphingolipid - physiology | Inflammation - immunology | Lymph Nodes - immunology | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Brain - drug effects | Sphingosine - pharmacology | Sphingosine - analogs & derivatives | Animals | Gap Junctions - physiology | Immune System - drug effects | Multiple Sclerosis - immunology | Sphingosine - therapeutic use | Lysophospholipids - physiology | Multiple Sclerosis - drug therapy | Review
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e64050
Sphingosine-1-phosphate (S1P) is a pluripotent lipophilic mediator working as a ligand for G-protein coupled S1P receptors (S1PR), which is currently... 
PRESENILIN | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | PROTEIN | MULTIPLE-SCLEROSIS | ALZHEIMERS-DISEASE | MULTIDISCIPLINARY SCIENCES | SPHINGOSINE-1-PHOSPHATE | A-BETA | GAMMA-SECRETASE ACTIVITY | T-CELLS | IMMUNOMODULATORY DRUG FTY720 | Propylene Glycols - pharmacology | Sulfhydryl Compounds - pharmacology | Amyloid beta-Peptides - biosynthesis | Humans | Fingolimod Hydrochloride | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Brain - drug effects | Brain - metabolism | Sphingosine - pharmacology | Amyloid Precursor Protein Secretases - metabolism | Sphingosine - analogs & derivatives | Animals | Signal Transduction - drug effects | Propylene Glycols - chemistry | Brain - pathology | Sulfhydryl Compounds - chemistry | Mice | Mice, Inbred BALB C | Neurons - metabolism | Neurons - drug effects | Sphingosine - chemistry | Disease Models, Animal | Phosphates | Regulators | Neurosciences | Multiple sclerosis | Laboratories | Neuropathology | Antagonists | Kinases | Neuromodulation | Modulators | Sphingosine 1-phosphate | Proteins | Lipophilic | Signal transduction | Receptors | Metabolites | Alzheimer's disease | Pharmaceutical sciences | Enzymes | Sphingosine kinase | Immunoglobulins | Neurodegenerative diseases | Transgenic mice | Pharmacology | Medicine | Signaling | Brain research | FTY720 | β-Amyloid | Autoimmune diseases | Alzheimers disease | Pluripotency
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 02/2009, Volume 284, Issue 9, pp. 5467 - 5477
Novel immunomodulatory molecule FTY720 is a synthetic analog of myriocin, but unlike myriocin FTY720 does not inhibit serine palmitoyltransferase. Although... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | SPHINGOSINE KINASE TYPE-2 | APOPTOSIS | ANGIOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | IMMUNOSUPPRESSANT FTY720 | MICE | SPHINGOSINE-1-PHOSPHATE RECEPTORS | TANDEM MASS-SPECTROMETRY | MODULATION | IMMUNOMODULATORY DRUG FTY720 | Endothelium, Vascular - cytology | Oxidoreductases - antagonists & inhibitors | Lysophospholipids - metabolism | Up-Regulation | Phosphorylation | Humans | Endothelium, Vascular - drug effects | Serine C-Palmitoyltransferase - genetics | Endothelium, Vascular - enzymology | Lung - cytology | RNA, Messenger - metabolism | Lung - enzymology | Tandem Mass Spectrometry | Chromatography, Liquid | Sphingosine - metabolism | Immunosuppressive Agents - pharmacology | Propylene Glycols - pharmacology | Ceramides - metabolism | Oxidoreductases - metabolism | Oxidoreductases - genetics | RNA, Messenger - genetics | RNA, Small Interfering - pharmacology | Cells, Cultured | Fingolimod Hydrochloride | Pulmonary Artery - drug effects | Serine C-Palmitoyltransferase - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Pulmonary Artery - enzymology | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Pulmonary Artery - cytology | Sphingosine - pharmacology | Sphingosine - analogs & derivatives | Lung - drug effects | Lipids and Lipoproteins | Metabolism, Regulation, and Signaling
Journal Article
Journal of Neuroimmunology, ISSN 0165-5728, 2014, Volume 270, Issue 1, pp. 13 - 21
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 8/2011, Volume 17, Issue 8, pp. 939 - 948
Journal Article